立体定向体部放射治疗对颅外寡转移癌患者的疗效。

Stereotactic body radiotherapy results for extracranial oligometastatic cancer patients.

作者信息

Aral Ipek Pinar, İnan Gonca Altınışık, Arslan Suheyla Aytac, Aksakal Ali Kerim, Ozturk Huseyin Furkan, Caygın Yasin, Beyaz Havva, Akıncı Muhammet Bülent, Tezcan Yılmaz

机构信息

Radiation Oncology, Ankara Şehir Hastanesi, Radyasyon Onkolojisi Bölümü, Ankara Yildirim Beyazit Universitesi Tip Fakultesi, Ankara, Türkiye.

Ankara City Hospital, Bilkent Caddesi, Çankaya, Türkiye.

出版信息

Rep Pract Oncol Radiother. 2025 Feb 19;29(6):667-674. doi: 10.5603/rpor.103528. eCollection 2024.

DOI:10.5603/rpor.103528

PMID:40104656

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912888/

Abstract

BACKGROUND

The aim of study was to evaluate the oncological results of stereotactic body radiotherapy (SBRT) in de-novo oligometastatic (dOM) disease.

MATERIALS AND METHODS

Patients who underwent SBRT for dOM disease in Radiation Oncology Clinic of Hospitals were analyzed retrospectively. The endpoints of the study were overall survival (OS) and disease free survival (DFS).

RESULTS

84 patients with treated between 08.06.2019-15.11.2022 were analyzed. The median follow up was 26 (range 6-219) months. dOM subgroups were as follows: 37 (44.0%) synchronous dOM (sdOM); 31 (37%) metachronous oligorecurrence (mdOR) and 16 (19.0%) metachronous oligoprogression (mdOP). Grade 1 acute side effects (ASE) were observed in only 1 patient and no grade ≥ 2 a ASE were observed. Progression was observed in 45 (53.6%) of the patients. The median DFS was 8 (range 1-32) mo, 1y DFS was 44.5%; 2y DFS was 26.2%. Significantly higher DFS was obtained in mdOR than sdOM and mdOP [p = 0.020; hazard ratio (HR): 1.6; 95% confidence interval (CI): 0.75-3.68%]. The relationship between response assessment after SBRT and DFS was significant (p < 0.001; HR: 4.8; 95% CI: 1.9-12.2). Twenty-nine (34.5%) patients were ex and 55 (65.5%) were alive. 1y OS was 75.6%; 2y OS -61.2%; 3y OS -57.4% and the median OS value has not yet been reached. Lower OS was observed in sdOM compared to mdOP and mdOR (p = 0.035, HR: 0.45; 95% CI: 0.21-0.96). The relationship between response assessment after SBRT and OS was significant (p = 0.017; HR: 6.6; 95% CI: 1.7-25.7).

CONCLUSION

Higher DFS was observed in mdOR patients and lower OS was observed in sdOM patients. SBRT response in dOM patients may be a prognostic factor for DFS and OS.

摘要

背景

本研究的目的是评估立体定向体部放疗（SBRT）治疗初发寡转移（dOM）疾病的肿瘤学结果。

材料与方法

对在医院放射肿瘤诊所接受SBRT治疗dOM疾病的患者进行回顾性分析。研究的终点是总生存期（OS）和无病生存期（DFS）。

结果

分析了2019年6月8日至2022年11月15日期间接受治疗的84例患者。中位随访时间为26（范围6 - 219）个月。dOM亚组如下：37例（44.0%）同步dOM（sdOM）；31例（37%）异时寡复发（mdOR）和16例（19.0%）异时寡进展（mdOP）。仅1例患者观察到1级急性副作用（ASE），未观察到≥2级ASE。45例（53.6%）患者出现疾病进展。中位DFS为8（范围1 - 32）个月，1年DFS为44.5%；2年DFS为26.2%。mdOR组的DFS显著高于sdOM组和mdOP组[p = 0.020；风险比（HR）：1.6；95%置信区间（CI）：0.75 - 3.68%]。SBRT后反应评估与DFS之间的关系显著（p < 0.001；HR：4.8；95% CI：1.9 - 12.2）。29例（34.5%）患者已死亡，55例（65.5%）患者仍存活。1年OS为75.6%；2年OS为61.2%；3年OS为57.4%，中位OS值尚未达到。与mdOP和mdOR相比，sdOM组的OS较低（p = 0.035，HR：0.45；95% CI：0.21 - 0.96）。SBRT后反应评估与OS之间的关系显著（p = 0.017；HR：6.6；95% CI：1.7 - 25.7）。